Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome Bridging for CD19 CAR-T
NCT06220097Phase 2Active, not recruiting
- Start
- Feb 2022
- Primary completion
- Aug 2024
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in B cell lymphoma, acute lymphoblastic leukemia (ALL). Started Feb 2022; status: active, not recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
B cell lymphomaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06220097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220097.